Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
about
Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Evaluating the costs of glycem ...... s in the United Arab Emirates.
@en
Evaluating the costs of glycem ...... s in the United Arab Emirates.
@nl
type
label
Evaluating the costs of glycem ...... s in the United Arab Emirates.
@en
Evaluating the costs of glycem ...... s in the United Arab Emirates.
@nl
prefLabel
Evaluating the costs of glycem ...... s in the United Arab Emirates.
@en
Evaluating the costs of glycem ...... s in the United Arab Emirates.
@nl
P2093
P2860
P1476
Evaluating the costs of glycem ...... us in the United Arab Emirates
@en
P2093
Agata Schubert
Ahmed Kamal
Anders T Buchholt
Antoine C El Khoury
P2860
P304
P356
10.1080/03007995.2017.1310091
P407
P577
2017-04-28T00:00:00Z